stockrow
Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.23
0.00
0.00%
Follow GLAS
Alert me
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 2.17 | 3.98 |
Altman Z-Score |
(0.18) | 0.97 | 1.39 |
P/FCF ratio |
0.00 | 24.11 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.67) | (1.53) | (1.62) |
Beneish M-Score |
— | (2.25) | (3.38) |
P/Operating CF |
(331.65) | 53.26 | (195.93) |
P/B ratio |
0.00 | 5.62 | 8.83 |
Price to Tangible BV |
0.00 | 6.87 | 8.92 |
EV/Sales |
0.00 | 2.25 | 4.30 |
EV/EBITDA |
0.00 | 21.73 | 0.00 |
EV/Operating CF |
0.00 | 15.91 | 68.29 |
EV/FCF |
0.00 | 24.96 | (50.40) |
Quick Ratio |
0.42 | 0.66 | 0.66 |
Current Ratio |
0.56 | 0.99 | 1.78 |
Net Debt/EBITDA |
(0.73) | 0.74 | (64.84) |
Debt/Assets |
19.10% | 16.82% | 21.88% |
Debt/Equity |
0.87 | 0.67 | 0.85 |
Asset Turnover |
0.00 | 0.65 | 0.58 |
Operating CF/Net income |
(0.20) | (1.84) | (0.25) |
Capex/Depreciation |
(0.84) | (0.68) | (1.71) |
Interest Coverage |
(5.04) | 0.62 | (2.34) |
| 0.00% | (21.33%) | (56.40%) | |
| 0.00% | (5.03%) | (14.33%) | |
ROIC |
(33.43%) | 3.86% | (7.83%) |
Return on Tangible Assets |
(65.74%) | (7.29%) | (17.43%) |
Average Days of Receivables |
9.03 | 12.99 | 10.45 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
34.66% | 31.13% | 36.69% |
Intangible Assets out of Total Assets |
0.07 | 0.05 | 0.04 |
Share Based Compensation of Revenue |
4.75% | 6.52% | 7.36% |
Graham Net Nets |
0.00 | (0.38) | (0.23) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.62%) | (3.62%) | (6.21%) |
Free Cash Flow Yield |
0.00% | 4.15% | (2.14%) |
Revenue per Share |
2.23 | 2.67 | 2.22 |
Operating CF per Share |
0.32 | 0.38 | 0.14 |
Capex per Share |
(0.17) | (0.14) | (0.33) |
Free Cash Flow per Share |
0.15 | 0.24 | (0.19) |
Cash per Share |
0.45 | 0.49 | 0.24 |
Shareholders Equity per Share |
0.93 | 1.03 | 1.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.93 | 1.03 | 1.00 |
Free Cash Flow |
10.92 | 18.10 | (15.51) |
Working Capital |
(38.14) | (0.38) | 29.79 |
Capital Expenditures |
(12.31) | (10.29) | (26.96) |
Net Current Asset Value |
(187.48) | (166.71) | (168.71) |
EV/EBIT |
0.00 | 78.73 | 0.00 |
Capex to Sales |
0.08 | 0.05 | 0.15 |
Price to Operating Income |
0.00 | 76.06 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.07 | 0.07 | 0.07 |
Cash ROIC |
6.92% | 10.85% | (9.03%) |
Accounts Receivable Turnover |
0.00 | 36.10 | 29.45 |
Accounts Payable Turnover |
0.00 | 3.57 | 3.13 |
Inventory Turnover |
0.00 | 8.96 | 5.19 |
Average Days of Payables |
123.08 | 109.77 | 125.01 |
Days of Inventory on Hand |
40.40 | 50.26 | 91.15 |
Average Receivables |
— | 5.56 | 6.18 |
Average Payables |
— | 29.03 | 33.55 |
Average Inventory |
— | 11.55 | 20.24 |
Average Assets |
— | 307.14 | 314.53 |
Average Common Equity |
— | 72.39 | 79.90 |
Columns are period end dates · fundamentals updated 2 Nov 2026